3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
lutetium Lu 177 dotatate
10
Everolimus
5
lanreotide
4
gallium Ga 68 dotatate
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
olaparib
3
Temozolomide
3
Somatostatin
3
Capecitabine
3
surufatinib
2
pembrolizumab
2
copper dotatate CU-64
2
cabozantinib
2
amino-acid, glucose, and electrolyte solution
2
Specimen Handling
2
Octreotide
2
Lutetium-177
2
Lutetium
2
Injections
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
tivozanib
1
talazoparib
1
sintilimab
1
repotrectinib
1
lenvatinib
1
guarana powder
1
gadoteridol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroendocrine Tumors
×
gadoterate meglumine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled